

Jrgen Vestbo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/648643/jorgen-vestbo-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

445
papers

43,415
citations

97
h-index

200
g-index

502
ext. papers

51,117
ext. citations

9.6
avg, IF

7.28
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 445 | Should e-cigarettes be licensed as medicines?. <i>BMJ, The</i> , 2022 , 376, n2912 | 5.9 | 0 |
| 444 | Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms.. <i>PLoS ONE</i> , 2022 , 17, e0262898 ³⁻⁷ | 3.7 | 0 |
| 443 | Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD.. <i>European Respiratory Journal</i> , 2022 , | 13.6 | 0 |
| 442 | Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).. <i>Trials</i> , 2022 , 23, 307 | 2.8 | 1 |
| 441 | Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study.. <i>Respiratory Medicine</i> , 2022 , 197, 106852 | 4.6 | |
| 440 | Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021 , 57, | 13.6 | 6 |
| 439 | Exacerbation history, severity of dyspnoea and maintenance treatment predicts risk of future exacerbations in patients with COPD in the general population.. <i>Respiratory Medicine</i> , 2021 , 192, 106725 ⁴⁻⁶ | 4.6 | 1 |
| 438 | Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , | 10.2 | 7 |
| 437 | ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations. <i>European Respiratory Journal</i> , 2021 , | 13.6 | 5 |
| 436 | Increased serum SP-D in identification of high-risk smokers at high risk of COPD. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021 , 320, L1005-L1010 | 5.8 | |
| 435 | Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV. <i>Frontiers in Immunology</i> , 2021 , 12, 668113 | 8.4 | 0 |
| 434 | Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1963-1973 | 8.4 | 4 |
| 433 | Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. <i>Respiratory Research</i> , 2021 , 22, 155 | 7.3 | 1 |
| 432 | Transformations of practice in online exercise training for patients with COPD led by physiotherapists - a qualitative study. <i>Disability and Rehabilitation</i> , 2021 , 1-10 | 2.4 | |
| 431 | Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021 , 7, | 3.5 | 2 |
| 430 | The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea. <i>Sleep and Biological Rhythms</i> , 2021 , 19, 399-408 | 1.3 | |
| 429 | Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 910-920 | 10.2 | 5 |

| | | | |
|-----|--|------|----|
| 428 | Supernormal lung function and risk of COPD: A contemporary population-based cohort study. <i>EClinicalMedicine</i> , 2021 , 37, 100974 | 11.3 | 5 |
| 427 | Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021 , 223, 94-100 | 7 | |
| 426 | Importance of Early COPD in Young Adults for Development of Clinical COPD: Findings from the Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1245-1256 | 10.2 | 15 |
| 425 | Independent Association of Interleukin 6 With Low Dynamic Lung Function and Airflow Limitation in Well-Treated People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1690-1698 | 7 | 3 |
| 424 | Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 689-698 | 10.2 | 10 |
| 423 | Relationship between supernormal lung function and long-term risk of hospitalisations and mortality: a population-based cohort study. <i>European Respiratory Journal</i> , 2021 , 57, | 13.6 | 6 |
| 422 | Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021 , 58, | 13.6 | 5 |
| 421 | Management of chronic obstructive pulmonary disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021 , 82, 1-10 | 0.8 | 0 |
| 420 | Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19. <i>European Respiratory Journal</i> , 2021 , 58, | 13.6 | 1 |
| 419 | Stigma: an unmet public health priority in COPD. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 955-956 | 35.1 | 1 |
| 418 | Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease. <i>Respiratory Medicine</i> , 2021 , 186, 106529 | 4.6 | |
| 417 | Another public health catastrophe.. <i>Lancet, The</i> , 2021 , 398, 2243 | 40 | 1 |
| 416 | Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. <i>ERJ Open Research</i> , 2020 , 6, | 3.5 | 1 |
| 415 | Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. <i>Respiratory Medicine</i> , 2020 , 173, 106185 | 4.6 | 2 |
| 414 | Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020 , 158, 952-964 | 5.3 | 15 |
| 413 | Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis. <i>European Clinical Respiratory Journal</i> , 2020 , 7, 1757274 | 2 | 9 |
| 412 | Outcomes consequent to "early" COPD for interventional studies. <i>European Respiratory Journal</i> , 2020 , 55, | 13.6 | 1 |
| 411 | FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , 2020 , 15, 1135-1142 | 3 | 11 |

| | | | |
|-----|---|------|----|
| 410 | Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk. <i>International Journal of COPD</i> , 2020 , 15, 543-552 | 3 | 7 |
| 409 | Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 1307-1310 | 10.2 | 5 |
| 408 | A rational approach to e-cigarettes: challenging ERS policy on tobacco harm reduction. <i>European Respiratory Journal</i> , 2020 , 55, | 13.6 | 1 |
| 407 | Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , 2020 , 55, | 13.6 | 17 |
| 406 | Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. <i>BMJ Open Respiratory Research</i> , 2020 , 7, | 5.6 | 14 |
| 405 | Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020 , 221, 1973-1977 | 7 | 6 |
| 404 | Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2020 , 10, e035640 | 3 | 6 |
| 403 | Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020 , 75, 520-527 | 7.3 | 43 |
| 402 | Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 210-218 | 10.2 | 20 |
| 401 | A new Cochrane review on electronic cigarettes for smoking cessation: should we change our practice?. <i>European Respiratory Journal</i> , 2020 , 56, | 13.6 | 6 |
| 400 | Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020 , 6, | 3.5 | 7 |
| 399 | Real-World Data and Randomised Controlled Trials: The Salford Lung Study. <i>Advances in Therapy</i> , 2020 , 37, 977-997 | 4.1 | 6 |
| 398 | Obstructive sleep apnea and hypertriglyceridaemia share common genetic background: Results of a twin study. <i>Journal of Sleep Research</i> , 2020 , 29, e12979 | 5.8 | 11 |
| 397 | The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 2170-2184 | 9.3 | 90 |
| 396 | Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020 , 71, 3214-3221 | 11.6 | 4 |
| 395 | Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 671-680 | 10.2 | 37 |
| 394 | Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?. <i>Clinics in Chest Medicine</i> , 2020 , 41, 463-474 | 5.3 | 5 |
| 393 | Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. <i>Respiratory Research</i> , 2020 , 21, 263 | 7.3 | |

| | | | |
|-----|--|------|-----|
| 392 | Telemediated Training in the Home as a Part of the Everyday Life and Practice With Very Severe Chronic Obstructive Pulmonary Disease. <i>Qualitative Health Research</i> , 2020 , 30, 2132-2145 | 3.9 | 4 |
| 391 | COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020 , 29, | 9.8 | 25 |
| 390 | Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. <i>Respiratory Research</i> , 2020 , 21, 2027-3 | 7.3 | 6 |
| 389 | Automatic oxygen titration with O2matic [®] to patients admitted with COVID-19 and hypoxemic respiratory failure. <i>European Clinical Respiratory Journal</i> , 2020 , 7, 1833-695 | 2 | 5 |
| 388 | The global impact of Aspergillus infection on COPD. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 241 | 3.5 | 17 |
| 387 | Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD: a contemporary population-based cohort. <i>Thorax</i> , 2020 , 75, 944-954 | 7.3 | 8 |
| 386 | Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020 , 10, | 3 | 5 |
| 385 | βAdrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. <i>Thorax</i> , 2019 , 74, 934-940 | 7.3 | 5 |
| 384 | Prospective observational study in patients with obstructive lung disease: NOVELTY design. <i>ERJ Open Research</i> , 2019 , 5, | 3.5 | 12 |
| 383 | Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials. <i>ERJ Open Research</i> , 2019 , 5, | 3.5 | 13 |
| 382 | Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. <i>International Journal of COPD</i> , 2019 , 14, 853-861 | 3 | 10 |
| 381 | Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. <i>Respiratory Research</i> , 2019 , 20, 63 | 7.3 | 17 |
| 380 | Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2166-2177 | 15.1 | 60 |
| 379 | Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. <i>Scientific Reports</i> , 2019 , 9, 4064 | 4.9 | 11 |
| 378 | Was the implementation strategy of the ProACT trial adequately proactive?. <i>Breathe</i> , 2019 , 15, 77-80 | 1.8 | 2 |
| 377 | Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019 , 5, | 3.5 | 3 |
| 376 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019 , 53, | 13.6 | 722 |
| 375 | Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019 , 53, | 13.6 | 1 |

| | | | |
|-----|---|------|-----|
| 374 | Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. <i>Nature Genetics</i> , 2019 , 51, 494-505 | 36.3 | 119 |
| 373 | Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. <i>Respiratory Medicine</i> , 2019 , 155, 141-147 | 4.6 | 10 |
| 372 | Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 699-709 | 35.1 | 62 |
| 371 | Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry. <i>European Respiratory Journal</i> , 2019 , 54, | 13.6 | 26 |
| 370 | A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations. <i>ERJ Open Research</i> , 2019 , 5, | 3.5 | 10 |
| 369 | End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2019 , 160, 105814 | 4.6 | 7 |
| 368 | Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 29-39 | 4.7 | 8 |
| 367 | Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. <i>Respiratory Medicine</i> , 2019 , 147, 58-65 | 4.6 | 3 |
| 366 | Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. <i>European Respiratory Journal</i> , 2018 , 51, | 13.6 | 16 |
| 365 | βBlocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 608-614 | 4.7 | 14 |
| 364 | Effectiveness efficacy trials in COPD: how study design influences outcomes and applicability. <i>European Respiratory Journal</i> , 2018 , 51, | 13.6 | 15 |
| 363 | Left ventricular volume and wall stress are linked to lung function impairment in COPD. <i>International Journal of Cardiology</i> , 2018 , 261, 172-178 | 3.2 | 16 |
| 362 | The emerging Chinese COPD epidemic. <i>Lancet, The</i> , 2018 , 391, 1642-1643 | 4.0 | 4 |
| 361 | Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. <i>European Respiratory Journal</i> , 2018 , 51, | 13.6 | 17 |
| 360 | Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 51-57 | 10.2 | 97 |
| 359 | Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018 , 73, 431-438 | 7.3 | 36 |
| 358 | At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1540-1551 | 10.2 | 94 |
| 357 | Long-Acting βAgonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 1641-1644 | 10.2 | 3 |

| | | | |
|-----|---|------|-----|
| 356 | Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 1076-1084 | 40 | 300 |
| 355 | Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018 , 51, | 13.6 | 38 |
| 354 | Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , 2018 , 51, | 13.6 | 17 |
| 353 | Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2037-2047.e10 | 11.5 | 95 |
| 352 | Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. <i>Human Molecular Genetics</i> , 2018 , 27, 3801-3812 | 5.6 | 19 |
| 351 | Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018 , 13, 1125-1134 | 3 | 8 |
| 350 | Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1126-1137 | 15.1 | 31 |
| 349 | Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , 2018 , 39, 3128-3134 | 9.5 | 17 |
| 348 | Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. <i>Respiratory Medicine</i> , 2018 , 141, 198-206 | 4.6 | 8 |
| 347 | Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , 2018 , 52, | 13.6 | 8 |
| 346 | Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 47-55 | 10.2 | 34 |
| 345 | The revised GOLD 2017 COPD categorization in relation to comorbidities. <i>Respiratory Medicine</i> , 2018 , 134, 79-85 | 4.6 | 34 |
| 344 | Automated oxygen control with O2matic during admission with exacerbation of COPD. <i>International Journal of COPD</i> , 2018 , 13, 3997-4003 | 3 | 7 |
| 343 | Biomarkers to guide antibiotic therapy for COPD exacerbations. <i>The Cochrane Library</i> , 2018 , | 5.2 | 78 |
| 342 | Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis. <i>Frontiers in Immunology</i> , 2018 , 9, 3013 | 8.4 | 12 |
| 341 | The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. <i>International Journal of COPD</i> , 2018 , 13, 3885-3894 | 3 | 2 |
| 340 | What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs. <i>International Journal of COPD</i> , 2018 , 13, 3485-3492 | 3 | 11 |
| 339 | Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply. <i>Lancet, The</i> , 2018 , 392, 1113-1114 | 40 | 0 |

| | | | |
|-----|--|------|------|
| 338 | Validation of lung density indices by cardiac CT for quantification of lung emphysema. <i>International Journal of COPD</i> , 2018 , 13, 3321-3330 | 3 | 1 |
| 337 | Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018 , 52, | 13.6 | 102 |
| 336 | Exhaled breath condensate in chronic obstructive pulmonary disease: methodological challenges and clinical application 2018 , 57, | | 1 |
| 335 | Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , 2018 , 52, | 13.6 | 36 |
| 334 | Iron Deficiency in COPD Associates with Increased Pulmonary Artery Pressure Estimated by Echocardiography. <i>Heart Lung and Circulation</i> , 2017 , 26, 101-104 | 1.8 | 16 |
| 333 | Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. <i>European Respiratory Review</i> , 2017 , 26, | 9.8 | 59 |
| 332 | Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , 2017 , 22, 575-601 | 3.6 | 228 |
| 331 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017 , 49, | 13.6 | 398 |
| 330 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 557-582 | 10.2 | 1682 |
| 329 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149 | 0.7 | 27 |
| 328 | Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. <i>Clinical Chemistry</i> , 2017 , 63, 823-832 | 5.5 | 29 |
| 327 | Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. <i>Nature Genetics</i> , 2017 , 49, 426-432 | 36.3 | 201 |
| 326 | Paper acceptance time in respiratory research: room for improvement?. <i>European Respiratory Journal</i> , 2017 , 49, | 13.6 | 1 |
| 325 | Small airway dysfunction in well-treated never-smoking HIV-infected individuals. <i>European Respiratory Journal</i> , 2017 , 49, | 13.6 | 10 |
| 324 | Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017 , 57, 35-46 | 5.7 | 37 |
| 323 | Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017 , 103, 1536-1542 | 5.1 | 34 |
| 322 | Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1082-1083 | 10.2 | 4 |
| 321 | Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 1919-1929 | 40 | 235 |

| | | | |
|-----|---|------|-----|
| 320 | Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, 426-434 | 35.1 | 62 |
| 319 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , 2017 , 53, 128-149 | 0.7 | 247 |
| 318 | Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 49, | 13.6 | 256 |
| 317 | A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 114 | 3.5 | 9 |
| 316 | Biomarkers of collagen turnover are related to annual change in FEV in patients with chronic obstructive pulmonary disease within the ECLIPSE study. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 164 | 3.5 | 11 |
| 315 | COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , 2017 , 18, 90 | 7.3 | 13 |
| 314 | Susceptibility to exacerbation in COPD. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, e29 | 35.1 | 9 |
| 313 | Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017 , 31, 1973-1977 | 3.5 | 4 |
| 312 | Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 50, | 13.6 | 89 |
| 311 | Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 2247-2255 | 4.0 | 56 |
| 310 | The prognostic significance of lung function in stable heart failure outpatients. <i>Clinical Cardiology</i> , 2017 , 40, 1145-1151 | 3.3 | 11 |
| 309 | The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 955-959.e6 | 5.9 | 15 |
| 308 | Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2017 , 27, 25 | 3.2 | 8 |
| 307 | Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , 2017 , 131, 27-34 | 4.6 | 21 |
| 306 | Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 1096.e1-1096.e17 | 5.9 | 30 |
| 305 | Exposure Interaction: A Lifelong Phenomenon with Relevance to Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 947-948 | 10.2 | |
| 304 | The TRINITY study: Twitter discussion from a respirology journal club - Authors' reply. <i>Lancet Respiratory Medicine, the</i> , 2017 , 5, e26 | 35.1 | |
| 303 | Prevalence of airflow obstruction in patients with stable systolic heart failure. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 6 | 3.5 | 15 |

| | | | |
|-----|--|------|-----|
| 302 | Clinical trial research in focus: time to reflect on the design of exacerbation trials in COPD. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 466-468 | 35.1 | 2 |
| 301 | Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 881-888 | 10.2 | 38 |
| 300 | U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 1797-1807 | 11.5 | 163 |
| 299 | Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 17-22 | 10.2 | 27 |
| 298 | Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. <i>Clinical Epidemiology</i> , 2017 , 9, 231-243 | 5.9 | 16 |
| 297 | Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , 2017 , 12, 2917-2928 | 3 | 23 |
| 296 | COPD 2016 , 751-766.e7 | | 1 |
| 295 | The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , 2016 , 194, 889-895 | 2.9 | 19 |
| 294 | Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , 2016 , 388, 963-73 | 40 | 256 |
| 293 | Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016 , 6, 114 | 8.9 | 13 |
| 292 | High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. <i>Respiratory Research</i> , 2016 , 17, 125 | 7.3 | 44 |
| 291 | A systematic review of breath analysis and detection of volatile organic compounds in COPD. <i>Journal of Breath Research</i> , 2016 , 10, 034002 | 3.1 | 27 |
| 290 | Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 980-989 | 35.1 | 27 |
| 289 | Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. <i>Chest</i> , 2016 , 149, 916-26 | 5.3 | 38 |
| 288 | Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 48-57 | 10.2 | 37 |
| 287 | Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 965-74 | 10.2 | 260 |
| 286 | A comparison of COPD patients with and without ACOS in the ECLIPSE study. <i>European Respiratory Journal</i> , 2016 , 47, 1559-62 | 13.6 | 29 |
| 285 | Chronic Mucus Hypersecretion and the Natural History of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 602-3 | 10.2 | 5 |

| | | | |
|-----|--|------|-----|
| 284 | Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. <i>European Respiratory Journal</i> , 2016 , 47, 1365-73 | 13.6 | 46 |
| 283 | Absence of <i>Pneumocystis jirovecii</i> Colonization in Human Immunodeficiency Virus-Infected Individuals With and Without Airway Obstruction and With Undetectable Viral Load. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw044 | 1 | 5 |
| 282 | Decade of the lung--a call for action to promote lung health globally. <i>Lancet Respiratory Medicine</i> , 2016 , 4, e3-e4 | 35.1 | 2 |
| 281 | Treatable traits: toward precision medicine of chronic airway diseases. <i>European Respiratory Journal</i> , 2016 , 47, 410-9 | 13.6 | 487 |
| 280 | Psychometric Properties of the COPD-Specific Beliefs About Medicine Questionnaire in an Outpatient Population: A Rasch-Analysis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 3, 748-757 | 2.7 | 3 |
| 279 | Beta-blockers in COPD: time for reappraisal. <i>European Respiratory Journal</i> , 2016 , 48, 880-8 | 13.6 | 44 |
| 278 | Effectiveness of Fluticasone Furoate-Vilanterol in COPD. <i>New England Journal of Medicine</i> , 2016 , 375, 2607 | 59.2 | 3 |
| 277 | Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016 , 16, 713 | 4 | 42 |
| 276 | The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016 , 114, 27-37 | 4.6 | 76 |
| 275 | Personality Traits and Mental Symptoms are Associated with Impact of Chronic Obstructive Pulmonary Disease on Patients' Daily Life. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 773-778 | 2 | 4 |
| 274 | Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 454-62 | 35.1 | 83 |
| 273 | Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1817-26 | 40 | 263 |
| 272 | Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. <i>New England Journal of Medicine</i> , 2016 , 374, 2222-34 | 59.2 | 537 |
| 271 | Natural experiments and large databases in respiratory and cardiovascular disease. <i>European Respiratory Review</i> , 2016 , 25, 130-4 | 9.8 | 1 |
| 270 | Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. <i>New England Journal of Medicine</i> , 2016 , 375, 1253-60 | 59.2 | 136 |
| 269 | Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2016 , 119, 87-95 | 4.6 | 21 |
| 268 | Natural history of COPD: Focusing on change in FEV1. <i>Respirology</i> , 2016 , 21, 34-43 | 3.6 | 22 |
| 267 | Chronic obstructive pulmonary disease in patients with end-stage kidney disease on hemodialysis. <i>Hemodialysis International</i> , 2016 , 20, 68-77 | 1.7 | 12 |

| | | | |
|-----|--|------|-----|
| 266 | Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 303-12 | 4.7 | 93 |
| 265 | Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 27-34 | 4.7 | 98 |
| 264 | Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population. <i>Journal of General Internal Medicine</i> , 2015 , 30, 51-9 | 4 | 42 |
| 263 | Overweight and obesity may lead to under-diagnosis of airflow limitation: findings from the Copenhagen City Heart Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 5-13 | 2 | 28 |
| 262 | The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , 2015 , 70, 757-63 | 7.3 | 10 |
| 261 | Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015 , 373, 111-22 | 59.2 | 595 |
| 260 | Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility. <i>BMC Medical Informatics and Decision Making</i> , 2015 , 15, 8 | 3.6 | 24 |
| 259 | Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. <i>Chest</i> , 2015 , 148, 16-23 | 5.3 | 19 |
| 258 | Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015 , 308, L1114-24 | 5.8 | 24 |
| 257 | One-year change in health status and subsequent outcomes in COPD. <i>Thorax</i> , 2015 , 70, 420-5 | 7.3 | 40 |
| 256 | Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. <i>Chest</i> , 2015 , 147, 999-1007 | 5.3 | 204 |
| 255 | An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27 | 10.2 | 137 |
| 254 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 879-905 | 13.6 | 107 |
| 253 | Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015 , 46, 1308-21 | 13.6 | 292 |
| 252 | Prevention of COPD exacerbations: medications and other controversies. <i>ERJ Open Research</i> , 2015 , 1, | 3.5 | 12 |
| 251 | Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. <i>Thorax</i> , 2015 , 70, 862-72 | 7.3 | 29 |
| 250 | Fibrinogen and α -antitrypsin in COPD exacerbations. <i>Thorax</i> , 2015 , 70, 1014-21 | 7.3 | 14 |
| 249 | Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015 , 109, 1147-54 | 4.6 | 31 |

| | | | |
|-----|--|------|-----|
| 248 | Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , 2015 , 109, 1138-46 | 4.6 | 56 |
| 247 | Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. <i>Thorax</i> , 2015 , 70, 33-40 | 7.3 | 61 |
| 246 | Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15076 | 51.1 | 270 |
| 245 | The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 160 | 3.5 | 36 |
| 244 | The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2015 , 16, 101 | 7.3 | 34 |
| 243 | Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015 , 10, 293-307 | 3 | 18 |
| 242 | Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 523-5 | 10.2 | 273 |
| 241 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015 , 24, 159-72 | 9.8 | 50 |
| 240 | Medically treated exacerbations in COPD by GOLD 1-4: A valid, robust, and seemingly low-biased definition. <i>Respiratory Medicine</i> , 2015 , 109, 1562-8 | 4.6 | 22 |
| 239 | Changes in GOLD: today and tomorrow. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 424-6 | 35.1 | 3 |
| 238 | Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. <i>Respirology</i> , 2015 , 20, 101-7 | 3.6 | 50 |
| 237 | Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 23-34 | 2.7 | 56 |
| 236 | Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 204-213 | 2.7 | 6 |
| 235 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014 , 69, 718-23 | 7.3 | 118 |
| 234 | Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2014 , 108, 1647-54 | 4.6 | 18 |
| 233 | Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , 2014 , 83, 2093-101 | 4.7 | 23 |
| 232 | Prevalence of night-time dyspnoea in COPD and its implications for prognosis. <i>European Respiratory Journal</i> , 2014 , 43, 1590-8 | 13.6 | 35 |
| 231 | Changes in physical activity and all-cause mortality in COPD. <i>European Respiratory Journal</i> , 2014 , 44, 1199-209 | 3.0 | 100 |

| | | | |
|-----|---|------|-----|
| 230 | Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. <i>Respiratory Research</i> , 2014 , 15, 103 | 7.3 | 38 |
| 229 | Association between vitamin D status and COPD phenotypes. <i>Lung</i> , 2014 , 192, 493-7 | 2.9 | 10 |
| 228 | COPD: definition and phenotypes. <i>Clinics in Chest Medicine</i> , 2014 , 35, 1-6 | 5.3 | 73 |
| 227 | Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. <i>BMC Pulmonary Medicine</i> , 2014 , 14, 43 | 3.5 | 32 |
| 226 | Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. <i>Respiratory Medicine</i> , 2014 , 108, 729-36 | 4.6 | 69 |
| 225 | Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2014 , 108, 1336-44 | 4.6 | 32 |
| 224 | COPD drugs: the urgent need for innovation. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 14-5 | 35.1 | 4 |
| 223 | Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014 , 44, 304-23 | 13.6 | 112 |
| 222 | Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014 , 69, 666-72 | 7.3 | 102 |
| 221 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 1022-30 | 10.2 | 117 |
| 220 | A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study. <i>Chest</i> , 2014 , 145, 408A | 5.3 | 2 |
| 219 | Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. <i>Scientific World Journal, The</i> , 2014 , 2014, 140736 | 2.2 | 15 |
| 218 | Validation of the i-BODE index as a predictor of hospitalization and mortality in patients with COPD participating in pulmonary rehabilitation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014 , 11, 381-7 | 2 | 24 |
| 217 | Surfactant protein D is a candidate biomarker for subclinical tobacco smoke-induced lung damage. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014 , 306, L887-95 | 5.8 | 20 |
| 216 | Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014 , 51, 678-87 | 5.7 | 17 |
| 215 | Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. <i>Respiratory Research</i> , 2014 , 15, 147 | 7.3 | 33 |
| 214 | Socioeconomic status and prognosis of COPD in Denmark. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014 , 11, 431-7 | 2 | 30 |
| 213 | S51 Circulating Desmosine Relates To Cardiovascular Comorbidity, Coronary Artery Calcification Score (cacs), Systemic Inflammation And Mortality In Patients With Copd. <i>Thorax</i> , 2014 , 69, A28-A29 | 7.3 | 1 |

| | | | |
|-----|--|------|------|
| 212 | Susceptibility to chronic mucus hypersecretion, a genome wide association study. <i>PLoS ONE</i> , 2014 , 9, e91621 | 3.7 | 19 |
| 211 | Reorganisation of acute referral to an emergency department resulted in fewer admissions for chronic obstructive pulmonary disease but in higher rates of non-invasive ventilation. <i>Danish Medical Journal</i> , 2014 , 61, A4958 | 3.8 | 1 |
| 210 | Reply: correctly defining criteria for diagnosing chronic obstructive pulmonary disease matters. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 230-1 | 10.2 | 6 |
| 209 | Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 2353-61 | 27.4 | 253 |
| 208 | Impact of diagnostic criteria on the prevalence of COPD. <i>Clinical Respiratory Journal</i> , 2013 , 7, 297-303 | 1.7 | 14 |
| 207 | Vitamin D, vitamin D binding protein, lung function and structure in COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1578-88 | 4.6 | 34 |
| 206 | Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013 , 107, 1376-84 | 4.6 | 243 |
| 205 | The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , 2013 , 41, 1017-22 | 13.6 | 65 |
| 204 | Factors associated with change in exacerbation frequency in COPD. <i>Respiratory Research</i> , 2013 , 14, 79 | 7.3 | 47 |
| 203 | The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 367-77 | 2 | 57 |
| 202 | Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 347-65 | 10.2 | 3654 |
| 201 | Resting heart rate is a predictor of mortality in COPD. <i>European Respiratory Journal</i> , 2013 , 42, 341-9 | 13.6 | 74 |
| 200 | Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. <i>Human Genetics</i> , 2013 , 132, 79-90 | 6.3 | 39 |
| 199 | Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 543-50 | 35.1 | 76 |
| 198 | Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2013 , 107, 1722-30 | 4.6 | 23 |
| 197 | NICE and GOLD response. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 442 | 35.1 | 1 |
| 196 | Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 210-23 | 35.1 | 249 |
| 195 | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 129-36 | 35.1 | 183 |

| | | | |
|-----|---|------|-----|
| 194 | Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 382-6 | 10.2 | 206 |
| 193 | FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. <i>European Respiratory Journal</i> , 2013 , 42, 1391-401 | 13.6 | 70 |
| 192 | Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?. <i>Annals of Nutrition and Metabolism</i> , 2013 , 63, 239-47 | 4.5 | 34 |
| 191 | Predictors of objective cough frequency in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 943-9 | 10.2 | 62 |
| 190 | Reply: Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1368 | 10.2 | |
| 189 | A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , 2013 , 41, 12-7 | 13.6 | 21 |
| 188 | 'Highlights from this issue' in the November issue of Thorax. <i>Thorax</i> , 2013 , 68, 387-8 | 7.3 | 1 |
| 187 | High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 1005-12 | 3.9 | 40 |
| 186 | Short telomere length, lung function and chronic obstructive pulmonary disease in 46,396 individuals. <i>Thorax</i> , 2013 , 68, 429-35 | 7.3 | 118 |
| 185 | Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013 , 42, 636-46 | 13.6 | 139 |
| 184 | Characteristics of undertreatment in COPD in the general population. <i>Chest</i> , 2013 , 144, 1811-1818 | 5.3 | 29 |
| 183 | Enzyme-linked immunosorbent assay characterization of basal variation and heritability of systemic microfibrillar-associated protein 4. <i>PLoS ONE</i> , 2013 , 8, e82383 | 3.7 | 15 |
| 182 | Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure. <i>International Journal of COPD</i> , 2013 , 8, 215-9 | 3 | 24 |
| 181 | Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. <i>PLoS ONE</i> , 2013 , 8, e82243 | 3.7 | 55 |
| 180 | Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. <i>Current Drug Targets</i> , 2013 , 14, 235-45 | 3 | 19 |
| 179 | Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 1238-47 | 10.2 | 88 |
| 178 | The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?. <i>Clinical Respiratory Journal</i> , 2012 , 6, 208-14 | 1.7 | 116 |
| 177 | Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. <i>Thorax</i> , 2012 , 67, 701-8 | 7.3 | 122 |

| | | | |
|-----|---|------|-----|
| 176 | Can patients with COPD self-manage?. <i>Lancet, The</i> , 2012 , 380, 624-5 | 4.0 | 13 |
| 175 | Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , 2012 , 13, 291-7 | 5.9 | 167 |
| 174 | Are pharmacists reducing COPD'S impact through smoking cessation and assessing inhaled steroid use?. <i>Respiratory Medicine</i> , 2012 , 106, 230-4 | 4.6 | 8 |
| 173 | Is chronic obstructive pulmonary disease associated with increased arterial stiffness?. <i>Respiratory Medicine</i> , 2012 , 106, 397-405 | 4.6 | 14 |
| 172 | Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1065-72 | 10.2 | 288 |
| 171 | A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. <i>Human Molecular Genetics</i> , 2012 , 21, 947-57 | 5.6 | 181 |
| 170 | Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 100 | 3 | 28 |
| 169 | Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 975-81 | 10.2 | 305 |
| 168 | Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 982-8 | 10.2 | 159 |
| 167 | GOLD and the fixed ratio. <i>International Journal of COPD</i> , 2012 , 7, 663; author reply 664 | 3 | |
| 166 | The association between aortic augmentation index and cardiovascular risk factors in a large unselected population. <i>Journal of Human Hypertension</i> , 2012 , 26, 476-84 | 2.6 | 37 |
| 165 | Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. <i>European Respiratory Journal</i> , 2012 , 39, 38-45 | 13.6 | 150 |
| 164 | Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , 2012 , 7, e37483 | 3.7 | 521 |
| 163 | Substantial need for early diagnosis, rehabilitation and treatment of chronic obstructive pulmonary disease. <i>Danish Medical Journal</i> , 2012 , 59, A4396 | 3.8 | 12 |
| 162 | Prevalence of COPD in Copenhagen. <i>Respiratory Medicine</i> , 2011 , 105, 410-7 | 4.6 | 45 |
| 161 | Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. <i>Respiratory Medicine</i> , 2011 , 105, 1338-44 | 4.6 | 21 |
| 160 | Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. <i>Liver International</i> , 2011 , 31, 1381-7 | 7.9 | 5 |
| 159 | Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , 2011 , 5, 44-9 | 1.7 | 55 |

| | | | |
|-----|---|------|-----|
| 158 | Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. <i>Respiratory Research</i> , 2011 , 12, 3 | 7.3 | 71 |
| 157 | Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , 2011 , 12, 71 | 7.3 | 54 |
| 156 | Recommendations for epidemiological studies on COPD. <i>European Respiratory Journal</i> , 2011 , 38, 1261-77 | 13.6 | 95 |
| 155 | Current controversies and future perspectives in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 507-13 | 10.2 | 83 |
| 154 | Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 604-11 | 10.2 | 202 |
| 153 | Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 317-22 | 10.2 | 122 |
| 152 | To use or not to use: clinical decision making in the face of uncertainty. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 284-5 | 10.2 | 3 |
| 151 | The EXACT-Pro: measuring exacerbations of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 287-8 | 10.2 | 11 |
| 150 | Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. <i>Respiratory Care</i> , 2011 , 56, 477-87 | 2.1 | 50 |
| 149 | Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. <i>New England Journal of Medicine</i> , 2011 , 365, 2541-2 | 59.2 | 105 |
| 148 | Candidate genes for COPD in two large data sets. <i>European Respiratory Journal</i> , 2011 , 37, 255-63 | 13.6 | 39 |
| 147 | GOLD and the fixed ratio. <i>European Respiratory Journal</i> , 2011 , 38, 481-2; author reply 482-4 | 13.6 | 6 |
| 146 | C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. <i>Thorax</i> , 2011 , 66, 197-204 | 7.3 | 55 |
| 145 | Impact of non-linear smoking effects on the identification of gene-by-smoking interactions in COPD genetics studies. <i>Thorax</i> , 2011 , 66, 903-9 | 7.3 | 22 |
| 144 | Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. <i>European Respiratory Journal</i> , 2011 , 37, 508-15 | 13.6 | 103 |
| 143 | Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , 2011 , 365, 1184-92 | 59.2 | 654 |
| 142 | Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011 , 8, 121-35 | 2 | 38 |
| 141 | Clinical Assessment of COPD 2011 , 21-31 | | |

| | | | |
|-----|---|------|------|
| 140 | Cardiovascular morbidity in COPD: A study of the general population. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 5-10 | 2 | 42 |
| 139 | Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. <i>Clinical Respiratory Journal</i> , 2010 , 4, 208-14 | 1.7 | 18 |
| 138 | Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010 , 35, 532-9 | 13.6 | 54 |
| 137 | Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. <i>American Journal of Hypertension</i> , 2010 , 23, 180-5 | 2.3 | 77 |
| 136 | Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 331-6 | 2 | 28 |
| 135 | Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 605-13 | 10.2 | 28 |
| 134 | Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38 | 59.2 | 1840 |
| 133 | Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2010 , 104, 849-57 | 4.6 | 148 |
| 132 | Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. <i>Respiratory Medicine</i> , 2010 , 104, 1297-303 | 4.6 | 38 |
| 131 | Genetic influences on Chronic Obstructive Pulmonary Disease - a twin study. <i>Respiratory Medicine</i> , 2010 , 104, 1890-5 | 4.6 | 45 |
| 130 | Chronic obstructive pulmonary disease phenotypes: the future of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 598-604 | 10.2 | 678 |
| 129 | Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , 2010 , 65, 719-25 | 7.3 | 142 |
| 128 | The prognostic importance of lung function in patients admitted with heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 685-91 | 12.3 | 80 |
| 127 | Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. <i>Chest</i> , 2010 , 138, 1125-32 | 5.3 | 64 |
| 126 | Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010 , 11, 122 | 7.3 | 752 |
| 125 | The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , 2009 , 4, 149-56 | 3 | 34 |
| 124 | Lung function decline in COPD trials. <i>European Respiratory Journal</i> , 2009 , 33, 708-9; author reply 709-10 | 13.6 | 3 |
| 123 | Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. <i>European Respiratory Journal</i> , 2009 , 34, 641-7 | 13.6 | 314 |

| | | | |
|-----|--|------|-----|
| 122 | Prevalence and progression of osteoporosis in patients with COPD: results from the TOWARDS a Revolution in COPD Health study. <i>Chest</i> , 2009 , 136, 1456-1465 | 5.3 | 202 |
| 121 | Increased T-regulatory cells within lymphocyte follicles in moderate COPD. <i>European Respiratory Journal</i> , 2009 , 34, 89-94 | 13.6 | 53 |
| 120 | Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. <i>Thorax</i> , 2009 , 64, 950-5 | 7.3 | 30 |
| 119 | Methods for therapeutic trials in COPD: lessons from the TORCH trial. <i>European Respiratory Journal</i> , 2009 , 34, 1018-23 | 13.6 | 23 |
| 118 | Adherence to inhaled therapy, mortality and hospital admission in COPD. <i>Thorax</i> , 2009 , 64, 939-43 | 7.3 | 309 |
| 117 | A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. <i>European Respiratory Journal</i> , 2009 , 33, 1039-44 | 13.6 | 65 |
| 116 | Biomarkers in chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2009 , 6, 543-5 | | 49 |
| 115 | Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1165-6 | 2.8 | 6 |
| 114 | Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , 2009 , 103, 136-43 | 4.6 | 70 |
| 113 | Improved survival prediction from lung function data in a large population sample. <i>Respiratory Medicine</i> , 2009 , 103, 442-8 | 4.6 | 32 |
| 112 | Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , 2009 , 103, 1572-9 | 4.6 | 59 |
| 111 | COPD phenotype description using principal components analysis. <i>Respiratory Research</i> , 2009 , 10, 41 | 7.3 | 44 |
| 110 | Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009 , 10, 59 | 7.3 | 234 |
| 109 | Sex differences in emphysema and airway disease in smokers. <i>Chest</i> , 2009 , 136, 1480-1488 | 5.3 | 76 |
| 108 | Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. <i>European Journal of Human Genetics</i> , 2008 , 16, 1083-90 | 5.3 | 31 |
| 107 | Evidence for an asthma risk locus on chromosome Xp: a replication linkage study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008 , 63, 1235-8 | 9.3 | 6 |
| 106 | CD8 chemokine receptors in chronic obstructive pulmonary disease. <i>Clinical and Experimental Immunology</i> , 2008 , 154, 56-63 | 6.2 | 13 |
| 105 | Chronic obstructive pulmonary disease in patients admitted with heart failure. <i>Journal of Internal Medicine</i> , 2008 , 264, 361-9 | 10.8 | 84 |

| | | | |
|-----|--|------|-----|
| 104 | Statistical analysis of COPD exacerbations. <i>European Respiratory Journal</i> , 2008 , 32, 1421-2 | 13.6 | 3 |
| 103 | Natural histories of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2008 , 5, 878-83 | | 49 |
| 102 | Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). <i>European Respiratory Journal</i> , 2008 , 31, 869-73 | 13.6 | 486 |
| 101 | Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 500-5 | 10.2 | 235 |
| 100 | Identification of a novel asthma susceptibility gene on chromosome 1qter and its functional evaluation. <i>Human Molecular Genetics</i> , 2008 , 17, 1890-903 | 5.6 | 45 |
| 99 | Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 332-8 | 10.2 | 566 |
| 98 | Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. <i>Thorax</i> , 2008 , 63, 1064-9 | 7.3 | 111 |
| 97 | COPD, diagrams and traditions: time to move on?. <i>Thorax</i> , 2008 , 63, 755-6 | 7.3 | 1 |
| 96 | Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. <i>European Respiratory Journal</i> , 2008 , 32, 17-24 | 13.6 | 76 |
| 95 | COPD-related morbidity and mortality after smoking cessation: status of the evidence. <i>European Respiratory Journal</i> , 2008 , 32, 844-53 | 13.6 | 178 |
| 94 | MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 1033-9 | 10.2 | 104 |
| 93 | COPD stage and risk of hospitalization for infectious disease. <i>Chest</i> , 2008 , 134, 46-53 | 5.3 | 51 |
| 92 | The many "small COPDs": COPD should be an orphan disease. <i>Chest</i> , 2008 , 134, 623-627 | 5.3 | 78 |
| 91 | CD4-regulatory cells in COPD patients. <i>Chest</i> , 2007 , 132, 156-63 | 5.3 | 90 |
| 90 | Association of PTGDR gene polymorphisms with asthma in two Caucasian populations. <i>Genes and Immunity</i> , 2007 , 8, 398-403 | 4.4 | 23 |
| 89 | Quantitative linkage genome scan for atopy in a large collection of Caucasian families. <i>Human Genetics</i> , 2007 , 121, 83-92 | 6.3 | 13 |
| 88 | A functional CD86 polymorphism associated with asthma and related allergic disorders. <i>Journal of Medical Genetics</i> , 2007 , 44, 509-15 | 5.8 | 20 |
| 87 | Systemic inflammation and progression of COPD. <i>Thorax</i> , 2007 , 62, 469-70 | 7.3 | 7 |

| | | | |
|----|--|------|------|
| 86 | Chronic cough and phlegm in young adults: should we worry?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 2-3 | 10.2 | 6 |
| 85 | C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 175, 250-5 | 10.2 | 391 |
| 84 | Use of different exhaled nitric oxide multiple flow rate models in COPD. <i>European Respiratory Journal</i> , 2007 , 29, 651-9 | 13.6 | 40 |
| 83 | A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. <i>Chest</i> , 2007 , 131, 682-689 | 5.3 | 99 |
| 82 | Exhaled CO, a predictor of lung function?. <i>Respiratory Medicine</i> , 2007 , 101, 581-6 | 4.6 | 7 |
| 81 | Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2007 , 356, 775-89 | 59.2 | 2457 |
| 80 | Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 464a-465 | 10.2 | 1 |
| 79 | Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 252-6 | | 18 |
| 78 | Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 79-83 | 10.2 | 386 |
| 77 | The natural history of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2006 , 27, 627-43 | 13.6 | 174 |
| 76 | Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene. <i>Thorax</i> , 2006 , 61, 874-9 | 7.3 | 19 |
| 75 | Developing COPD: a 25 year follow up study of the general population. <i>Thorax</i> , 2006 , 61, 935-9 | 7.3 | 377 |
| 74 | Potential misclassification of causes of death from COPD. <i>European Respiratory Journal</i> , 2006 , 28, 781-5 | 13.6 | 103 |
| 73 | Inhaled corticosteroids and decline of lung function in community residents with asthma. <i>Thorax</i> , 2006 , 61, 100-4 | 7.3 | 89 |
| 72 | COPD: the dangerous underestimate of 15%. <i>Lancet, The</i> , 2006 , 367, 1216-9 | 4.0 | 159 |
| 71 | Smoking reduction and biomarkers in two longitudinal studies. <i>Addiction</i> , 2006 , 101, 1516-22 | 4.6 | 26 |
| 70 | Family based association analysis of the IL2 and IL15 genes in allergic disorders. <i>European Journal of Human Genetics</i> , 2006 , 14, 227-35 | 5.3 | 35 |
| 69 | Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. <i>Journal of Medical Genetics</i> , 2006 , 43, e10 | 5.8 | 19 |

| | | | |
|----|--|------|-----|
| 68 | Convergence of the epidemiology and pathology of COPD. <i>Thorax</i> , 2006 , 61, 86-8 | 7.3 | 57 |
| 67 | Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample: Findings from the Copenhagen City Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 79-83 | 10.2 | 248 |
| 66 | The severity of airways obstruction as a determinant of treatment response in COPD. <i>International Journal of COPD</i> , 2006 , 1, 209-18 | 3 | 12 |
| 65 | Factor V leiden homozygosity, dyspnea, and reduced pulmonary function. <i>Archives of Internal Medicine</i> , 2005 , 165, 2032-6 | | 13 |
| 64 | Smoking reduction intervention in a large population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 112-8 | 4.3 | 23 |
| 63 | Smoking cessation intervention in a large randomised population-based study. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 285-92 | 4.3 | 57 |
| 62 | It is possible to help smokers in early motivational stages to quit. The Inter99 study. <i>Preventive Medicine</i> , 2005 , 40, 278-84 | 4.3 | 49 |
| 61 | COPD: a prevalence estimation model. <i>Respirology</i> , 2005 , 10, 594-602 | 3.6 | 8 |
| 60 | Measuring bronchodilation in COPD clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 379-84 | 3.4 | 83 |
| 59 | Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005 , 60, 301-4 | 7.3 | 45 |
| 58 | Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 460-4 | 10.2 | 64 |
| 57 | Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. <i>Thorax</i> , 2005 , 60, 343-9 | 7.3 | 17 |
| 56 | Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005 , 60, 992-7 | 7.3 | 170 |
| 55 | Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2005 , 25, 269-74 | 13.6 | 74 |
| 54 | Acceptance of the smoking cessation intervention in a large population-based study: the Inter99 study. <i>Scandinavian Journal of Public Health</i> , 2005 , 33, 138-45 | 3 | 30 |
| 53 | COPD in the ECRHS. <i>Thorax</i> , 2004 , 59, 89-90 | 7.3 | 3 |
| 52 | A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. <i>Nicotine and Tobacco Research</i> , 2004 , 6, 55-61 | 4.9 | 99 |
| 51 | Possible gene dosage effect of glutathione-S-transferases on atopic asthma: using real-time PCR for quantification of GSTM1 and GSTT1 gene copy numbers. <i>Human Mutation</i> , 2004 , 24, 208-14 | 4.7 | 89 |

| | | | |
|----|---|------|-----|
| 50 | Validation of a chronic obstructive pulmonary disease screening questionnaire for population surveys. <i>Respiratory Medicine</i> , 2004 , 98, 78-83 | 4.6 | 33 |
| 49 | Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. <i>Respiratory Medicine</i> , 2004 , 98, 1045-50 | 4.6 | 67 |
| 48 | Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2004 , 98, 1207-13 | 4.6 | 115 |
| 47 | Outpatient management of chronic obstructive pulmonary disease. <i>Clinical Medicine</i> , 2004 , 4, 220-4 | 1.9 | |
| 46 | Changes in alcohol intake and mortality: a longitudinal population-based study. <i>Epidemiology</i> , 2004 , 15, 222-8 | 3.1 | 71 |
| 45 | A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 627-33 | | 49 |
| 44 | Chronic bronchitis in an elderly population. <i>Age and Ageing</i> , 2003 , 32, 636-42 | 3 | 37 |
| 43 | Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2003 , 361, 449-56 | 4.0 | 961 |
| 42 | Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. <i>Treatments in Respiratory Medicine</i> , 2003 , 2, 67-74 | | 86 |
| 41 | Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. <i>Journal of Epidemiology and Community Health</i> , 2003 , 57, 412-6 | 5.1 | 64 |
| 40 | Social position and mortality from respiratory diseases in males and females. <i>European Respiratory Journal</i> , 2003 , 21, 821-6 | 13.6 | 62 |
| 39 | Inhaled glucocorticoids in COPD: immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003 , 168, 127 | 10.2 | 4 |
| 38 | Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. <i>European Respiratory Journal</i> , 2002 , 20, 819-25 | 13.6 | 218 |
| 37 | Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. <i>European Respiratory Journal</i> , 2002 , 20, 539-44 | 13.6 | 178 |
| 36 | Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. <i>Thorax</i> , 2002 , 57, 967-72 | 7.3 | 120 |
| 35 | Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. <i>American Journal of Epidemiology</i> , 2002 , 156, 994-1001 | 3.8 | 125 |
| 34 | Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. <i>European Respiratory Journal</i> , 2002 , 20, 799-805 | 13.6 | 410 |
| 33 | Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 166, 329-32 | 10.2 | 189 |

| | | | |
|----|---|------|-----|
| 32 | Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. <i>Annals of Internal Medicine</i> , 2002 , 136, 270-9 | 8 | 112 |
| 31 | Changes in smoking habits and risk of asthma: a longitudinal population based study. <i>European Respiratory Journal</i> , 2001 , 18, 549-54 | 13.6 | 42 |
| 30 | Epidemiology of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2001 , 17, 982-94 | 13.6 | 216 |
| 29 | Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 163, 690-3 | 10.2 | 45 |
| 28 | Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 1008-11 | 10.2 | 179 |
| 27 | Another piece of the inhaled corticosteroids-in-COPD puzzle. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 514-5 | 10.2 | 4 |
| 26 | Predictors of smoking reduction and cessation in a cohort of danish moderate and heavy smokers. <i>Preventive Medicine</i> , 2001 , 33, 46-52 | 4.3 | 68 |
| 25 | Molecular Diagnosis of Intermediate and Severe α -Antitrypsin Deficiency: MZ Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function Than MM Individuals. <i>Clinical Chemistry</i> , 2001 , 47, 56-62 | 5.5 | 39 |
| 24 | Increase in prevalence and severity of asthma in young adults in Copenhagen. <i>Thorax</i> , 2000 , 55, 833-6 | 7.3 | 40 |
| 23 | Prognostic value of nutritional status in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 160, 1856-61 | 10.2 | 726 |
| 22 | Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 1999 , 353, 1819-23 | 40 | 632 |
| 21 | Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. <i>European Respiratory Journal</i> , 1999 , 13, 1109-14 | 13.6 | 155 |
| 20 | A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country. Copenhagen Center for Prospective Population Studies. <i>European Journal of Epidemiology</i> , 1998 , 14, 579-85 | 12.1 | 27 |
| 19 | Mortality in women and men in relation to smoking. <i>International Journal of Epidemiology</i> , 1998 , 27, 27-32,8 | | 111 |
| 18 | A 15-year follow-up study of ventilatory function in adults with asthma. <i>New England Journal of Medicine</i> , 1998 , 339, 1194-200 | 59.2 | 969 |
| 17 | Has risk associated with smoking increased? Results from the Copenhagen Center for Prospective Population Studies. <i>International Journal of Epidemiology</i> , 1997 , 26, 1214-8 | 7.8 | 5 |
| 16 | Alveolar damage in AIDS-related <i>Pneumocystis carinii</i> pneumonia. <i>Chest</i> , 1997 , 111, 1193-9 | 5.3 | 36 |
| 15 | Rapid detection of cytomegalovirus in bronchoalveolar lavage fluid and serum samples by polymerase chain reaction: correlation of virus isolation and clinical outcome for patients with human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , 1997 , 24, 878-83 | 11.6 | 3 |

| | | | |
|----|--|------|-----|
| 14 | Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly?. <i>American Journal of Hypertension</i> , 1997 , 10, 634-9 | 2.3 | 63 |
| 13 | Does cytomegalovirus predict a poor prognosis in <i>Pneumocystis carinii</i> pneumonia treated with corticosteroids? A note for caution. <i>Chest</i> , 1995 , 108, 411-4 | 5.3 | 40 |
| 12 | Prognostic value of interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995 , 151, 1058-62 | 10.2 | 21 |
| 11 | Chronic mucus hypersecretion in COPD and death from pulmonary infection. <i>European Respiratory Journal</i> , 1995 , 8, 1333-8 | 13.6 | 165 |
| 10 | Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. <i>European Respiratory Journal</i> , 1995 , 8, 1694-8 | 13.6 | 72 |
| 9 | Are respiratory symptoms and chronic airflow limitation really associated with an increased risk of respiratory cancer?. <i>International Journal of Epidemiology</i> , 1991 , 20, 375-8 | 7.8 | 13 |
| 8 | The single-breath nitrogen test, mortality, and cancer. <i>The American Review of Respiratory Disease</i> , 1990 , 142, 1022-5 | | 6 |
| 7 | Predictive value of the single-breath nitrogen test for hospitalization due to respiratory disease. <i>Lung</i> , 1990 , 168, 93-101 | 2.9 | 5 |
| 6 | Small-airways dysfunction in never smoking asbestos exposed Danish plumbers. <i>International Archives of Occupational and Environmental Health</i> , 1990 , 62, 209-12 | 3.2 | 3 |
| 5 | Long-term exposure to cement dust and later hospitalization due to respiratory disease. <i>International Archives of Occupational and Environmental Health</i> , 1990 , 62, 217-20 | 3.2 | 18 |
| 4 | Scintigraphic demonstration of the thoracic duct following oral ingestion of ¹²³ I-heptadecanoic acid. <i>Gastrointestinal Radiology</i> , 1989 , 14, 212-4 | | 4 |
| 3 | Should we continue using questionnaires on breathlessness in epidemiologic surveys?. <i>The American Review of Respiratory Disease</i> , 1988 , 137, 1114-8 | | 45 |
| 2 | The Natural History of COPD115-123 | | 1 |
| 1 | Re-assessing the importance of FEV1 decline134-142 | | 0 |